The discovery of the latest markers helps non-invasive diagnosis of liver cancer patients

A medical technology company focused on developing innovative technologies for early diagnosis of cancer, today announced new research results. A clinical study of liver cancer has demonstrated the great potential of LAM’s new DNA methylation-based biomarker to detect hepatocellular carcinoma (HCC) The detection sensitivity is 95% and the specificity is 97.5%.

In this study, stock samples of 130 subjects were collected, including: 60 subjects diagnosed with hepatocellular carcinoma (stage I to IV), 30 subjects without liver disease, 10 Subjects diagnosed with benign liver disease and 30 subjects diagnosed with breast cancer, colorectal cancer or lung cancer. DNA was extracted from the sample, the DNA was transformed with bisulfite, and DNA methylation was quantified using the IvyGene platform. After completing the data collection and analysis of all samples, blind the samples to calculate the test performance.

A total of 57 of the 60 samples taken from patients with hepatocellular carcinoma were correctly identified, with an overall calculated sensitivity of 95%. The sensitivity difference between detecting stage I and stage IV hepatocellular carcinoma was small (range 89% to 100%). Of the samples taken from cancer patients other than liver cancer, 90% of breast cancer samples, 80% of colorectal cancer samples, and 90% of lung cancer samples were correctly identified as non-liver cancer, and the total calculated specificity was 87%.

For details on best options for liver cancer treatment, do call us at +91 96 1588 1588 or write to cancerfax@gmail.com.

Susan Hau

Website |  + postsBio ⮌

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

• Susan Hau

  https://cancerfax.com/author/susan/

  Datopotamab deruxtecan-dlnk is approved by the USFDA for EGFR-mutated non-small cell lung cancer
• Susan Hau

  https://cancerfax.com/author/susan/

  PiggyBac Transposon System: A Revolutionary Tool in Cancer Gene Therapy
• Susan Hau

  https://cancerfax.com/author/susan/

  Neoadjuvant and adjuvant pembrolizumab is approved by the USFDA for resectable locally advanced head and neck squamous cell carcinoma
• Susan Hau

  https://cancerfax.com/author/susan/

  Taletrectinib is approved by the USFDA for ROS1-positive non-small cell lung cancer

• Comments Closed
• April 8th, 2020